Agilent Technologies

Agilent Technologies, Inc. (Agilent) makes instruments, software, consumables and services for analytical and clinical laboratories. Its Life Sciences and Diagnostics Markets Group sells instruments such as liquid chromatographs and mass spectrometers, pathology products and nucleic acid manufacturing for drug makers. Its Agilent CrossLab Group sells consumables, service contracts and software for the installed base of instruments.

Its Applied Markets Group sells to chemical, energy, environmental and food testing labs. Revenue was $6.95 billion in fiscal year 2025, which ended on October 31, 2025, and $1.88 billion in Q3 of fiscal year 2026. Agilent bought the pathology company Biocare in June 2026 for $950 million.

It has about 18,000 employees. The head office is in Santa Clara, California. Padraig McDonnell is President and Chief Executive Officer.

Agilent's price already includes a lasting recovery for a laboratory supplier whose growth depends on the budgets of drug makers, research labs and testing labs. After a weak fiscal year 2024, core revenue growth rose to 7.3% in Q3 of fiscal year 2026, and the non-GAAP operating margin rose to 28.3%. The recovery can still stop, because research funding, tariffs and demand in China can change quickly.

For the price to hold, three things must be true. Core revenue must keep growing at about 5% or more in fiscal year 2027. The Ignite cost program must keep the operating margin rising after the one-time tariff refunds of 2026.

And the Biocare purchase must add growth in pathology without a large charge. The Q4 2026 report with the fiscal year 2027 guidance, on November 23, 2026, is the next test. The quarterly reports in 2027 show whether growth holds.

1. Aug 26, 2026Passed

   Q3 fiscal 2026 results: core growth and marginCore revenue growth of 5% or more with a higher operating margin passes; lower growth or a lower margin fails.Outcome: Core revenue grew 7.3%, the non-GAAP operating margin rose to 28.3%, and Agilent raised its full-year guidance.
2. Nov 23, 2026Pending

   Q4 fiscal 2026 results and fiscal 2027 guidanceFiscal year 2027 guidance with core revenue growth of about 5% or more and higher non-GAAP EPS passes; guidance for lower growth fails.
3. Feb 2027 · est.Pending

   Q1 fiscal 2027 results: growth without tariff refundsCore revenue growth of 5% or more and a higher non-GAAP operating margin than a year earlier pass; a lower margin fails.

Every passed and failed checkpoint across all picks

• September 4, 2026Boon Hwee Koh retired as Chairperson of the Board after 23 years on the Board. The Board appointed Glenn Boehnlein, the former Chief Financial Officer of Stryker, as a director.
• August 26, 2026Agilent reported Q3 fiscal year 2026 results. Revenue rose 8.1% to $1.88 billion, or 7.3% on a core basis, and non-GAAP EPS rose 18% to $1.62, with $0.06 from tariff refunds. Agilent raised its fiscal year 2026 guidance to revenue of $7.49 billion to $7.51 billion and non-GAAP EPS of $6.18 to $6.21.
• June 25, 2026Agilent issued $600 million of 4.90% senior notes due January 2032.

Last earnings

August 26, 2026 (8-K on sec.gov)

Next earnings

November 23, 2026, as the company confirmed.

• 8-KChange of directors or officers and Investor disclosureFiled September 8, 2026 · a-20260902
• 10-QQuarterly report for the period ended Jul 31, 2026Filed September 1, 2026 · a-20260731
• 8-KEarnings releaseFiled August 26, 2026 · Press release and exhibits
• 8-KNew material agreement and New debt or financial obligationFiled June 25, 2026 · Read it on sec.gov
• 10-QQuarterly report for the period ended Apr 30, 2026Filed June 1, 2026 · a-20260430
• 8-KEarnings release and Change of directors or officersFiled May 27, 2026 · Press release and exhibits
• 8-KChange of directors or officers and Investor disclosureFiled May 4, 2026 · a-20260504
• 8-KCurrent reportFiled April 3, 2026 · a-20260331
• 8-KChange to shareholder rights or bylaws and Shareholder vote resultsFiled March 20, 2026 · a-20260318
• 8-KChange of directors or officersFiled March 6, 2026 · a-20260305

Every filing on SEC EDGAR (CIK 1090872)

• Demand depends on the budgets of drug makers, academic and government labs, and testing labs. Lower research funding or weak pharmaceutical spending reduces orders for instruments, which customers can delay.
• Tariffs and trade rules change costs and demand. Q3 2026 results included a net benefit of $17 million from tariff refunds, which the guidance does not expect again. Agilent holds more inventory, 120 days in July 2026, to reduce tariff risks.
• About 52% of revenue is in currencies other than the U.S. dollar. A stronger dollar lowers reported revenue and earnings.
• Acquisitions such as Biocare in 2026 and BIOVECTRA in 2024 raise goodwill, which was $5.0 billion in July 2026. Weak results from them can cause impairment charges.
• Agilent expects capital spending of about $450 million in fiscal year 2026, mainly for more manufacturing capacity for advanced therapeutics in Frederick, Colorado. Low use of this capacity would lower returns.

Agilent funds its business with cash flow, senior unsecured notes and commercial paper. At July 31, 2026, cash and cash equivalents were $1,758 million. Read more

Dividend yield

0.6% (last 12 months, at today’s price of $177.88)

Paid per share

$1.02 in the last 12 months (4 payments)

Current annual rate

$1.02 ($0.255 × 4 a year)

Payout ratio

22% of the last fiscal year’s earnings (the year that ended October 31, 2025)

Latest ex-dividend date

October 6, 2026, $0.255 per share

Dividends per share by year

From 2020 to 2025, the dividend grew by about 6.6% a year. From 2015 to 2025, the dividend grew by about 3.7% a year.

Source: company filings and market data, read on November 10, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.